Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

BioNow Precision Medicine Conference

The 2025 Bionow Precision Medicine Conference dives into how tailored healthcare is redefining the future of medicine. This event brings together key voices from across [...]

Go to Top